Literature DB >> 8554088

Squamous cell carcinoma of the conjunctiva in a patient with the acquired immunodeficiency syndrome.

C Muccioli1, R Belfort, M Burnier, N Rao.   

Abstract

PURPOSE: To alert ophthalmologists to the possibility of human immunodeficiency virus (HIV) infection in individuals with conjunctival squamous cell carcinoma.
METHODS: We treated a 24-year-old patient with the acquired immunodeficiency syndrome who developed a limbal mass. The mass was excised and examined by routine histologic and immunohistochemical methods.
RESULTS: The histopathologic examination disclosed infiltrating squamous cell carcinoma with features of spindle cell carcinoma. Frequent abnormal mitotic figures were present in this neoplasia.
CONCLUSIONS: Squamous cell carcinoma with histologic features of aggressive behavior in a young individual should alert physicians to the possibility of HIV infection. Such patients may require frequent follow-up examination, even after complete excision of the tumor.

Entities:  

Mesh:

Year:  1996        PMID: 8554088     DOI: 10.1016/s0002-9394(14)70541-0

Source DB:  PubMed          Journal:  Am J Ophthalmol        ISSN: 0002-9394            Impact factor:   5.258


  5 in total

1.  Squamous Cell Carcinoma in HIV/AIDS.

Authors:  Solomon Guramatunhu
Journal:  Community Eye Health       Date:  2003

Review 2.  Conjunctival melanoma in Southwestern Nigeria: a case series and review of literature.

Authors:  Oluyemi Fasina; Olayiwola A Oluwasola
Journal:  Int Ophthalmol       Date:  2017-06-19       Impact factor: 2.031

3.  Conjunctival melanoma: risk factors for recurrence, exenteration, metastasis, and death in 150 consecutive patients.

Authors:  C L Shields
Journal:  Trans Am Ophthalmol Soc       Date:  2000

Review 4.  Ocular disease in AIDS.

Authors:  I Kuo; N A Rao
Journal:  Springer Semin Immunopathol       Date:  1999

Review 5.  Anterior segment manifestations of human immunodeficiency virus/acquired immune deficiency syndrome.

Authors:  Jyotirmay Biswas; S Sudharshan
Journal:  Indian J Ophthalmol       Date:  2008 Sep-Oct       Impact factor: 1.848

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.